Drug Trial Radar · NCT07158437
Phase 1 Study of SL-325 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Sep 18, 2025
Primary completion
Jul 16, 2026
Study completion Jul 16, 2026
Sponsor
- Lead sponsor
- Shattuck Labs, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
SL-325Biological
DR3 blocking antibody
Placebo (Normal Saline)Other
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Day 1 through 75 days after last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.